Search Within

Shanu Modi

Formats
  1. Meeting Abstract (150)
  2. Journal Article (99)
  3. Review (11)
  4. Correspondence (2)
  5. Editorial (2)
  6. Research Letter (1)
Groups
  1. Breast Medicine Service (265)
  2. Department of Medicine (265)
  3. Solid Tumor Oncology Division (265)
  4. Survivorship Research (113)
  5. GSK Faculty (104)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (88)

More Groups

People
  1. Clifford Hudis (79)
  2. Larry Norton (53)
  3. Sarat Chandarlapaty (49)
  4. Sujata Patil (44)
  5. Chau Dang (41)
  6. Komal Jhaveri (34)

More People

Years
  1. 2025 (5)
  2. 2024 (23)
  3. 2023 (15)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (21)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Cancer Research (50)
  3. Annals of Oncology (27)
  4. Breast Cancer Research and Treatment (14)
  5. Clinical Cancer Research (10)
  6. Clinical Breast Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (66)
  2. American Association for Cancer Research (64)
  3. Oxford University Press (33)
  4. Elsevier Inc. (19)
  5. Springer (18)
  6. Nature Publishing Group (13)

More Publishers

Results (265)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferation
    Journal Article

    Roychowdhury, T.; McNutt, S. W.; Pasala, C.; Nguyen, H. T.; Thornton, D. T.; Sharma, S.; Botticelli, L.; Digwal, C. S.; Joshi, S.; Yang, N.; more...
    Nature Communications (2024)

    Fulltext@MSK | Save
  • Managed care considerations in the treatment of HER2-positive advanced breast cancer: A closer look at recent advances for improved patient outcomes
    Journal Article

    Modi, S.
    Journal of Managed Care Medicine (2024)

    Fulltext@MSK | Save
  • Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03
    Meeting Abstract

    Saura, C.; Cortés, J.; Modi, S.; Kim, S. B.; Hamilton, E. P.; Hurvitz, S. A.; Krop, I. E.; Curigliano, G.; Iwata, H.; Im, S. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies
    Meeting Abstract

    Park, Y. H.; Cortes, J.; Modi, S.; Hurvitz, S. A.; Bianchini, G.; Iwata, H.; Shitara, K.; Siena, S.; Goto, Y.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
    Meeting Abstract

    Sands, J.; Tolaney, S. M.; Ueno, N. T.; Spira, A. I.; Yamamoto, N.; Janjigian, Y. Y.; Naito, Y.; Damodaran, S.; Meric-Bernstam, F.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan
    Meeting Abstract

    Mai, N.; Klar, M.; Ferraro, E.; Bromberg, M.; Chen, Y.; Razavi, P.; Modi, S.; Chandarlapaty, S.; Walsh, E. M.; Drago, J. Z.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer
    Meeting Abstract

    Ferraro, E.; Moiso, E.; Safonov, A.; Cabel, L.; Loudon, L.; Dang, C. T.; Shen, S.; Jhaveri, K. L.; Robson, M. E.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Meeting Abstract

    Moiso, E.; Ferraro, E.; Cabel, L.; Safonov, A.; Ahmed, M.; An, J. A. R.; Jhaveri, K. L.; Norton, L.; Robson, M. E.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: Subgroup analysis of the DESTINY-Breast04 study
    Journal Article

    Yamashita, T.; Sohn, J. H.; Tokunaga, E.; Niikura, N.; Park, Y. H.; Lee, K. S.; Chae, Y. S.; Xu, B.; Wang, X.; Im, S. A.; more...
    Breast Cancer (2024)

    Fulltext@MSK | Save
  • Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
    Journal Article

    Garrido, C.; Manoogian, M.; Ghambire, D.; Lucas, S.; Karnoub, M.; Olson, M. T.; Hicks, D. G.; Tozbikian, G.; Prat, A.; Ueno, N. T.; more...
    Virchows Archiv (2024)

    Fulltext@MSK | Save